50 results on '"Ingelsson, Martin"'
Search Results
2. CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer’s disease PSEN1 M146L mutation
3. Multi‐phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations
4. In vivo imaging of alpha-synuclein with antibody-based PET
5. In vivo imaging of alpha-synuclein with antibody-based PET
6. Size Matters - The Impact of Nucleus Size on Results From Spatial Transcriptomics
7. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease
8. In vivo imaging of synaptic density with [11C]UCB-J PET in two mouse models of neurodegenerative disease
9. ABBV-0805, a novel antibody selective for soluble aggregated alpha-synuclein, prolongs lifespan and prevents buildup of alpha-synuclein pathology in mouse models of Parkinson's disease
10. Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice
11. Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice
12. Phosphorylated α-Synuclein in Skin Non-Myelinating Schwann Cells: A New Biomarker for Multiple System Atrophy
13. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium
14. Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease
15. Quantitative Interaction Proteomics of Neurodegenerative Disease Proteins
16. CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s Disease
17. Corrigendum to “Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathways” [Free Rad. Biol. Med. (2017) 421–431]
18. Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology
19. Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathways
20. Extensive uptake of α-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage
21. Stability of Proteins in Dried Blood Spot Biobanks
22. Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease
23. 567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease
24. In vitro characterization of fibrillar amyloid, tau deposits, and activated astrocytes in Arctic APP and sporadic Alzheimer's disease brain using, 3H-PIB and 3H-THK5117 and 3H-Deprenyl in comparison to immunostaining
25. Changes in secondary structure of α-synuclein during oligomerization induced by reactive aldehydes
26. Corrigendum to “The amyloid-beta degradation pattern in plasma—A possible tool for clinical trials in Alzheimer’s disease” [Neurosci. Lett. 573 (2014) 7–12]
27. In Vivo Seeding and Cross-Seeding of Localized Amyloidosis
28. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice
29. The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease
30. Neurofilament ELISA validation.
31. The Arctic amyloid-β precursor protein (AβPP) mutation results in distinct plaques and accumulation of N- and C-truncated Aβ
32. Engulfment adapter PTB domain containing 1 interacts with and affects processing of the amyloid-β precursor protein
33. Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood Cells
34. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro
35. The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties
36. Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease
37. Neurofilament ELISA validation
38. CALHM1 P86L polymorphism does not alter amyloid-β or tau in cerebrospinal fluid
39. A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice
40. The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links α-synuclein causing rapid formation of stable oligomers
41. No Association between CALHM1 and Alzheimer's Disease Risk
42. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease
43. Expression of APP pathway mRNAs and proteins in Alzheimer’s disease
44. Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families
45. Transcriptional Up-Regulation and Activation of Initiating Caspases in Experimental Glaucoma
46. Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms
47. Transcriptional and conformational changes of the tau molecule in Alzheimer's disease
48. Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer’s disease
49. P3-229 Analysis of gene expression in the Alzheimer's disease brain
50. APOE ε3/ε4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer’s disease diagnosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.